Correlation between Oral Mucosal Changes and Intestinal Histopathology in Inflammatory Bowel Disease Patients: Impact of Clinical Activity and Psychosocial Stress
Downloads
IBD (inflammatory bowel disease), which is a combination of ulcerative colitis and Crohn's disease, is a chronic inflammatory disease that has substantial effects outside the intestines. Since changes in the oral mucosa correspond to the clinical manifestation of intestinal inflammation, changes in the oral mucosa of patients with IBD are common. The aim of the study was to establish how the clinical and psychosocial level of stress interacts with the clinical disease level of activity, as well as the variation in the intestinal and oral mucosal histological severity of the IBD patients. 177 participants with IBD were recruited (63 with Crohn disease, and 44 with ulcerative colitis). All patient data were collected between June 2024 and June 2025 at different hospitals in Iraq. Clinical disease activity was measured using the Harvey-Bradshaw Index (in Crohn victims) and the Mayo Score (in ulcerative colitis victims). The mucosal changes were identified and categorized with the help of oral examination and were classified in terms of the specific lesion. Lintel histology was assessed under three variables, namely mild, moderate, and severe inflammation. The psychosocial levels of stress were measured with the help of the Perceived Stress Scale (PSS). There was also a considerable difference between the presence of oral lesions and the current clinical disease (p<0.001) as well as moderate to severe intestinal inflammation (p=0.003). The oral lesions acquired by the patient were dose-dependent, and more oral lesions would be acquired when the patient was under a lot of stress (73.1%). A satisfactory clinical outcome to assess the condition of the disease can be the lesions in the IBD mucosa of the mouth that can be a powerful indicator of the severity of the intestinal histology and clinical activity. Psychosocial stress, which is a complication of the oral symptoms, also indicates the degree of whole-person care which influences the psychological well-being.
1. Li, C. J., Wang, Y. K., Zhang, S. M., Ren, M. D., & He, S. X. (2023). Global burden of inflammatory bowel disease 1990-2019: A systematic examination of the disease burden and twenty-year forecast. World Journal of Gastroenterology, 29 (42), 5751.
2. Aniwan, S., Santiago, P., Loftus Jr, E. V., & Park, S. H. (2022). The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries. United European gastroenterology journal, 10 (10), 1063-1076.
3. Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J. Crohn’s Colitis. 2019;2020:4–22.
4. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. J. Crohn’s Colitis. 2012;6:991–1030.
5. Sandborn WJ, Feagan BG, Loftus E V., et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease. Gastroenterology. 2020;158:2123–2138.
6. Lankarani, K. B., Sivandzadeh, G. R., & Hassanpour, S. (2013). Oral manifestation in inflammatory bowel disease: a review. World journal of gastroenterology: WJG, 19 (46), 8571.
7. Besharat, S., Amiriani, T., Roshandel, G., Besharat, M., Semnani, S., & Kamkar, M. (2012). Depressive mood and disease activity in inflammatory bowel disease. Arab Journal of Gastroenterology, 13 (3), 136-138.
8. Trindade, I. A., & Sirois, F. M. (2021). The prospective effects of self-compassion on depressive symptoms, anxiety, and stress: a study in inflammatory bowel disease. Journal of Psychosomatic Research, 146, 110429.
9. Fairbrass, K. M., Gracie, D. J., & Ford, A. C. (2022). Relative contribution of disease activity and psychological health to prognosis of inflammatory bowel disease during 6.5 years of longitudinal follow-up. Gastroenterology, 163 (1), 190-203.
10. Colombel JF, Reinisch W, Mantzaris GJ, et al. Randomised clinical trial: Deep remission in biologic and immunomodulator naïve patients with Crohn’s disease - A SONIC post hoc analysis. Aliment. Pharmacol. Ther. 2015;41:734–746.
11. Narang, V., Kaur, R., Garg, B., Mahajan, R., Midha, V., Sood, N., & Sood, A. (2018). Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis. Intestinal research, 16 (1), 55.
12. Geboes, K., Riddell, R., Öst, A., Jensfelt, B., Persson, T., & Löfberg, R. (2000). A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut, 47 (3), 404-409.
13. Saxena, A.; Fletcher, E.; Larsen, B.; Baliga, M.S.; Durstine, J.L.; Fayad, R. Effect of exercise on chemically-induced colitis in adiponectin-deficient mice. J. Inflamm. 2012, 9, 30.
14. Parragi L, Fournier N, Zeitz J, et al. Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-Year Follow-up Data From the Swiss IBD Cohort Study. J. Crohn’s Colitis. 2018;12:811–818.
15. Keegan, D., Byrne, K., Cullen, G., Doherty, G. A., Dooley, B., & Mulcahy, H. E. (2015). The stressometer: A simple, valid, and responsive measure of psychological stress in inflammatory bowel disease patients. Journal of Crohn's and Colitis, 9 (10), 881-885.
16. Marrie, R. A., Graff, L. A., Fisk, J. D., Patten, S. B., & Bernstein, C. N. (2021). The relationship between symptoms of depression and anxiety and disease activity in IBD over time. Inflammatory bowel diseases, 27 (8), 1285-1293.
17. Laranjeira, N., Fonseca, J., Meira, T., Freitas, J., Valido, S., & Leitão, J. (2015). Oral mucosa lesions and oral symptoms in inflammatory bowel disease patients. Arquivos de gastroenterologia, 52 (2), 105-110.
18. Alatab S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2020;5:17–30.
19. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–2778.
20. Knowles SR, Graff LA, Wilding H, et al. Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses - Part I. Inflamm. Bowel Dis. 2018;24:742–751.
21. Aldini, R.; Micucci, M.; Cevenini, M.; Fato, R.; Bergamini, C.; Nanni, C.; Cont, M.; Camborata, C.; Spinozzi, S.; Montagnani, M.; et al. Anti-inflammatory effect of phytosterols in experimental murine colitis model: Prevention, induction, remission study. PLoS ONE 2014, 9, e108112.
22. Valk ME Van Der, Mangen MJJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: Results from the COIN study. Gut. 2014;63:72–79.
23. Mirkov MU, Verstockt B, Cleynen I. Genetics of inflammatory bowel disease: beyond NOD2. Lancet Gastroenterol. Hepatol. 2017;2:224–234.


